BRPI0210541B8 - compostos derivados diamínicos; compostos intermediários para a preparação destes compostos; composição medicinal compreendendo ditos compostos; e usos dos mesmos para prevenir e/ou tratar trombose, embolia e outras doenças relacionadas - Google Patents
compostos derivados diamínicos; compostos intermediários para a preparação destes compostos; composição medicinal compreendendo ditos compostos; e usos dos mesmos para prevenir e/ou tratar trombose, embolia e outras doenças relacionadasInfo
- Publication number
- BRPI0210541B8 BRPI0210541B8 BRPI0210541A BRPI0210541B8 BR PI0210541 B8 BRPI0210541 B8 BR PI0210541B8 BR PI0210541 A BRPI0210541 A BR PI0210541A BR PI0210541 B8 BRPI0210541 B8 BR PI0210541B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- embolism
- thrombus formation
- infarction
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001187105 | 2001-06-20 | ||
JP2001243046 | 2001-08-09 | ||
JP2001311808 | 2001-10-09 | ||
JP2001398708 | 2001-12-28 | ||
PCT/JP2002/002683 WO2003000657A1 (fr) | 2001-06-20 | 2002-03-20 | Derives de diamine |
PCT/JP2002/006141 WO2003000680A1 (fr) | 2001-06-20 | 2002-06-20 | Derives de diamine |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0210541A BR0210541A (pt) | 2004-06-22 |
BRPI0210541B1 BRPI0210541B1 (pt) | 2018-12-04 |
BRPI0210541B8 true BRPI0210541B8 (pt) | 2021-05-25 |
Family
ID=27519131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0210541-1 BRPI0210541B8 (pt) | 2001-06-20 | 2002-06-20 | compostos derivados diamínicos; compostos intermediários para a preparação destes compostos; composição medicinal compreendendo ditos compostos; e usos dos mesmos para prevenir e/ou tratar trombose, embolia e outras doenças relacionadas |
Country Status (18)
Country | Link |
---|---|
US (1) | US20050245565A1 (pt) |
EP (1) | EP1405852B9 (pt) |
JP (2) | JP4128138B2 (pt) |
KR (1) | KR100863113B1 (pt) |
CN (1) | CN1826333B (pt) |
AU (1) | AU2002346300C1 (pt) |
BR (1) | BRPI0210541B8 (pt) |
CA (1) | CA2451605C (pt) |
DK (1) | DK1405852T3 (pt) |
ES (1) | ES2389027T3 (pt) |
IL (2) | IL159438A0 (pt) |
LU (1) | LU92835I2 (pt) |
MX (1) | MXPA03011951A (pt) |
NO (2) | NO332919B1 (pt) |
PL (2) | PL220739B1 (pt) |
RU (1) | RU2319699C2 (pt) |
WO (1) | WO2003000680A1 (pt) |
ZA (1) | ZA200400926B (pt) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
TWI288745B (en) * | 2000-04-05 | 2007-10-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
WO2003000657A1 (fr) * | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
EP1415992B1 (en) * | 2001-08-09 | 2012-05-02 | Daiichi Sankyo Company, Limited | Diamine derivatives |
JP4109288B2 (ja) * | 2002-12-25 | 2008-07-02 | 第一三共株式会社 | ジアミン誘導体 |
US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア,インコーポレイテッド | サイトカイン阻害剤 |
EP1670739A4 (en) * | 2003-10-08 | 2007-08-08 | Bristol Myers Squibb Co | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS |
HUE039135T2 (hu) * | 2003-11-12 | 2018-12-28 | Daiichi Sankyo Co Ltd | Eljárás tiazolszármazék elõállítására |
CN1878778B (zh) * | 2003-11-12 | 2010-12-29 | 第一三共株式会社 | 噻唑衍生物的制备方法 |
JP4564792B2 (ja) * | 2004-07-12 | 2010-10-20 | 第一三共株式会社 | 血栓・塞栓の治療剤 |
JP5557410B2 (ja) * | 2004-07-13 | 2014-07-23 | 第一三共株式会社 | 経口投与による血栓・塞栓の予防治療剤 |
CN103214414B (zh) | 2005-09-16 | 2016-02-17 | 第一三共株式会社 | 旋光性的二胺衍生物及其制造方法 |
JP5187901B2 (ja) | 2006-08-30 | 2013-04-24 | 塩野義製薬株式会社 | ヒドラジンアミド誘導体 |
JP4463875B2 (ja) | 2007-03-29 | 2010-05-19 | 第一三共株式会社 | 医薬組成物 |
WO2009045761A1 (en) * | 2007-09-28 | 2009-04-09 | Absolute Science, Inc. | Compounds and methods for treating zinc matrix metalloprotease dependent diseases |
EP2283006B1 (en) | 2008-04-24 | 2015-02-25 | F2G Limited | Pyrrole antifungal agents |
JP5683273B2 (ja) | 2008-12-12 | 2015-03-11 | 第一三共株式会社 | 光学活性カルボン酸の製造方法 |
BRPI0923109A8 (pt) * | 2008-12-17 | 2016-06-07 | Daiichi Sankyo Co Ltd | método para a produção de derivados de diamina |
WO2010071164A1 (ja) | 2008-12-19 | 2010-06-24 | 第一三共株式会社 | 活性化血液凝固第X因子(FXa)阻害剤 |
EP2383272A4 (en) | 2009-01-13 | 2012-07-25 | Daiichi Sankyo Co Ltd | INHIBITOR OF AN ACTIVE FACTOR OF BLOOD COAGULATION |
EP2407457B1 (en) | 2009-03-10 | 2015-04-22 | Daiichi Sankyo Company, Limited | Process for producing diamine derivative |
JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
RU2012101649A (ru) | 2009-06-18 | 2013-07-27 | Дайити Санкио Компани, Лимитед | Фармацевтическая композиция, обладающая улучшенной растворимостью |
TW201200165A (en) | 2010-02-22 | 2012-01-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
TW201141544A (en) | 2010-02-22 | 2011-12-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
EP2540317A4 (en) | 2010-02-22 | 2014-04-16 | Daiichi Sankyo Co Ltd | SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION |
HUE031059T2 (en) | 2010-03-19 | 2017-06-28 | Daiichi Sankyo Co Ltd | Procedure for improving anticoagulant administration |
BR112012023649B1 (pt) | 2010-03-19 | 2021-06-08 | Daiichi Sankyo Company, Limited | Método para produção de cristais de forma ii de monoidrato de n1 -(5-cloropiridin-2-il)-n2 -((1s,2r,4s)-4-[(dimetilamino) carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino}ciclohexil)etanodiamida p-toluenossulfonato |
WO2011149110A1 (en) * | 2010-05-28 | 2011-12-01 | Daiichi Sankyo Company, Limited | Novel composition for the prevention and/or treatment of thromboembolism |
ES2619374T3 (es) | 2010-07-02 | 2017-06-26 | Daiichi Sankyo Company, Limited | Procedimiento de preparación de sal derivada de diamina ópticamente activa |
HUE035506T2 (en) | 2010-08-04 | 2018-05-02 | Daiichi Sankyo Co Ltd | Process for Preparing a Compound with a New Sandmeyer-Type Reaction Using a Nitric Dioxide Compound as a Reaction Catalyst |
CN103619883A (zh) | 2011-01-19 | 2014-03-05 | 拜耳知识产权有限责任公司 | 凝血因子抑制剂的结合蛋白 |
JP5860050B2 (ja) | 2011-07-08 | 2016-02-16 | 第一三共株式会社 | 製品の品質管理方法 |
BR112014002397B1 (pt) | 2011-08-10 | 2021-08-03 | Daiichi Sankyo Company, Limited | Formulação sólida na forma de tablete ou cápsula contendo derivado de diamida |
CN102516249A (zh) * | 2011-12-08 | 2012-06-27 | 成都苑东药业有限公司 | 一种抗凝血的二胺衍生物 |
CN103333091A (zh) * | 2011-12-08 | 2013-10-02 | 成都苑东药业有限公司 | 一种抗凝血的二胺衍生物 |
US20130158069A1 (en) | 2011-12-14 | 2013-06-20 | Daiichi Sankyo Company, Limited | Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment |
RU2665372C2 (ru) | 2012-09-03 | 2018-08-29 | Дайити Санкио Компани, Лимитед | Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона |
EP2980090A4 (en) * | 2013-03-29 | 2016-11-09 | Daiichi Sankyo Co Ltd | PROCESS FOR THE PREPARATION OF (1S, 4S, 5S -4-BROM-6-OXABICYCLO [3.2.1] OCTAN-7-ON |
TWI602803B (zh) | 2013-03-29 | 2017-10-21 | 第一三共股份有限公司 | 光學活性二胺衍生物之製造方法 |
ES2815352T3 (es) | 2014-02-18 | 2021-03-29 | Daiichi Sankyo Co Ltd | Procedimiento de producción de un inhibidor de factor X de la coagulación sanguínea activado (FXa) |
BR112017010439B1 (pt) | 2014-11-21 | 2023-03-07 | F2G Limited | Composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta, e, uso de um composto, de uma composição ou de uma combinação |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
EP3484893A1 (en) * | 2016-07-13 | 2019-05-22 | Mylan Laboratories Ltd. | Salt of amine-protected (1s,2r,4s)-1,2-amino-n,n-dimethylcyclohexane-4-carboxamide |
KR20180022125A (ko) * | 2016-08-23 | 2018-03-06 | 동화약품주식회사 | 디아민 유도체의 산부가염 및 이의 제조 방법 |
EP3318568A1 (en) | 2016-11-04 | 2018-05-09 | Esteve Química, S.A. | Preparation process of edoxaban tosylate monohydrate |
ES2722854B2 (es) | 2018-02-14 | 2019-12-20 | Moehs Iberica Sl | Procedimiento para preparar n-((1r,2s,5s)-2-((2-((5-cloropiridin-2-il)amino)-2-oxoacetil)amino)-5-(dimetilcarbamoil) ciclohexil)carbamato de terc-butilo |
KR102087080B1 (ko) | 2018-06-08 | 2020-03-10 | 주식회사 가피바이오 | 에독사반의 제조용 중간체의 제조 방법 및 에독사반의 제조 방법 |
KR102600044B1 (ko) * | 2018-08-01 | 2023-11-08 | 제이더블유중외제약 주식회사 | 에독사반 신규 염 |
CN111138357B (zh) * | 2018-11-06 | 2022-11-04 | 天津药物研究院有限公司 | 2-氧代-1,2-二氢喹啉类衍生物、其制备方法及其在医药上的应用 |
CN109836360B (zh) * | 2019-03-19 | 2021-08-13 | 南京恩泰医药科技有限公司 | 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物 |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
EP3744320A1 (en) | 2019-05-29 | 2020-12-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising edoxaban |
KR102480897B1 (ko) | 2019-09-09 | 2022-12-23 | 주식회사 종근당 | 디아민 유도체의 제조방법 |
KR20210050472A (ko) | 2019-10-28 | 2021-05-07 | 연성정밀화학(주) | 에독사반염 및 이를 포함하는 약제학적 조성물 |
KR102333564B1 (ko) | 2019-11-28 | 2021-12-01 | 동방에프티엘(주) | 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로 |
KR102090912B1 (ko) * | 2019-12-18 | 2020-03-18 | 유니셀랩 주식회사 | 신규한 결정형 형태의 에독사반 및 이의 제조방법 |
EP3838267A1 (en) | 2019-12-19 | 2021-06-23 | Biohorm, S.L. | Edoxaban tablets |
KR102513519B1 (ko) | 2020-06-08 | 2023-03-23 | 주식회사 파마코스텍 | 신규한 에독사반 벤젠술폰산염 1 수화물의 제조방법 |
CN111606827B (zh) * | 2020-06-23 | 2022-10-25 | 内蒙古京东药业有限公司 | 一种制备依度沙班手性胺中间体的方法 |
KR20220014858A (ko) | 2020-07-29 | 2022-02-07 | 주식회사 종근당 | 디아민 유도체의 결정형 및 이의 제조 방법 |
KR102577696B1 (ko) | 2020-11-16 | 2023-09-14 | 주식회사 보령 | 에독사반 토실산염 또는 그 수화물의 제조방법 |
KR20220087933A (ko) | 2020-12-18 | 2022-06-27 | 엠에프씨 주식회사 | 디아민 유도체의 제조방법 |
EP4262760A1 (en) | 2020-12-18 | 2023-10-25 | KRKA, d.d., Novo mesto | Edoxaban formulation containing no sugar alcohols |
KR102518204B1 (ko) | 2022-02-18 | 2023-04-05 | 주식회사 엔비피헬스케어 | 신규한 에독사반 프로필렌글리콜 용매화물 |
KR20230158354A (ko) | 2022-05-11 | 2023-11-20 | 엠에프씨 주식회사 | 에독사반 중간체의 신규 제조방법 및 이를 이용한 에독사반 제조방법 |
WO2024009206A1 (en) * | 2022-07-04 | 2024-01-11 | Ami Lifesciences Private Limited | A process for the preparation of edoxaban and its intermediates |
CN115594613B (zh) * | 2022-10-31 | 2024-04-19 | 上海柏狮生物科技有限公司 | 依度沙班中间体及其制备方法 |
WO2024121413A1 (en) | 2022-12-09 | 2024-06-13 | Synthon B.V. | Formulation comprising edoxaban and preparation thereof |
WO2024185438A1 (ja) * | 2023-03-09 | 2024-09-12 | 株式会社カネカ | アジド化合物、アミン化合物、及びエドキサバンの製造方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0224566A1 (en) * | 1985-06-07 | 1987-06-10 | The Upjohn Company | Antiarrhythmic use for aminocycloalkylamides |
AU8501291A (en) * | 1990-09-10 | 1992-03-30 | Upjohn Company, The | Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants |
IL100576A (en) | 1991-01-18 | 1995-11-27 | Eli Lilley And Company | Cephalosporin antibiotics |
US5430150A (en) * | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
JPH09503994A (ja) * | 1993-03-03 | 1997-04-22 | イーライ・リリー・アンド・カンパニー | バラノイド |
KR970001164B1 (ko) | 1993-06-09 | 1997-01-29 | 한국과학기술연구원 | 세팔로스포린계 항생제 및 그의 제조방법 |
TW270114B (pt) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
AU6856094A (en) | 1994-06-01 | 1995-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Oxadiazole derivative and medicinal composition thereof |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
US5726126A (en) | 1995-06-02 | 1998-03-10 | American Cyanamid Company | 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents |
DE19536783A1 (de) * | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope |
US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
IT1291823B1 (it) * | 1997-04-08 | 1999-01-21 | Menarini Ricerche Spa | Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche |
US6207679B1 (en) * | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
AU9280698A (en) * | 1997-09-30 | 1999-04-23 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
US6130349A (en) * | 1997-12-19 | 2000-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Catalytic compositions and methods for asymmetric allylic alkylation |
DE19814801A1 (de) * | 1998-04-02 | 1999-10-07 | Basf Ag | Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen |
BR9909597A (pt) * | 1998-04-21 | 2001-10-02 | Du Pont Pharm Co | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas |
AU5196399A (en) * | 1998-08-11 | 2000-03-06 | Daiichi Pharmaceutical Co., Ltd. | Novel sulfonyl derivatives |
AU2241400A (en) * | 1999-04-06 | 2000-10-12 | Yamanouchi Pharmaceutical Co., Ltd. | Novel thiazolobenzoimidazole derivative |
GB9909592D0 (en) * | 1999-04-26 | 1999-06-23 | Chirotech Technology Ltd | Process for the preparation of calanolide precursors |
EP1185488A1 (fr) * | 1999-06-15 | 2002-03-13 | Rhodia Chimie | Sulfonylamides et carboxamides et leur application en catalyse asymetrique |
US6492408B1 (en) * | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
US6132884A (en) * | 2000-01-14 | 2000-10-17 | Ticona Llc | Process for producing amorphous anisotrophic melt-forming polymers having a high degree of stretchability and polymers produced by same |
TWI288745B (en) * | 2000-04-05 | 2007-10-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
WO2003000657A1 (fr) * | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
EP1415992B1 (en) * | 2001-08-09 | 2012-05-02 | Daiichi Sankyo Company, Limited | Diamine derivatives |
-
2002
- 2002-06-20 US US10/481,629 patent/US20050245565A1/en not_active Abandoned
- 2002-06-20 BR BR0210541-1 patent/BRPI0210541B8/pt not_active IP Right Cessation
- 2002-06-20 WO PCT/JP2002/006141 patent/WO2003000680A1/ja active Application Filing
- 2002-06-20 CA CA2451605A patent/CA2451605C/en not_active Expired - Lifetime
- 2002-06-20 CN CN028160401A patent/CN1826333B/zh not_active Expired - Lifetime
- 2002-06-20 DK DK02743653.4T patent/DK1405852T3/da active
- 2002-06-20 MX MXPA03011951A patent/MXPA03011951A/es active IP Right Grant
- 2002-06-20 RU RU2004101279/04A patent/RU2319699C2/ru not_active Application Discontinuation
- 2002-06-20 PL PL398653A patent/PL220739B1/pl unknown
- 2002-06-20 ES ES02743653T patent/ES2389027T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP02743653A patent/EP1405852B9/en not_active Expired - Lifetime
- 2002-06-20 KR KR1020037016618A patent/KR100863113B1/ko active Protection Beyond IP Right Term
- 2002-06-20 AU AU2002346300A patent/AU2002346300C1/en not_active Expired
- 2002-06-20 JP JP2003507084A patent/JP4128138B2/ja not_active Expired - Lifetime
- 2002-06-20 PL PL367532A patent/PL214669B1/pl unknown
- 2002-06-20 IL IL15943802A patent/IL159438A0/xx active IP Right Grant
-
2003
- 2003-12-17 NO NO20035634A patent/NO332919B1/no not_active IP Right Cessation
- 2003-12-18 IL IL159438A patent/IL159438A/en active IP Right Review Request
-
2004
- 2004-02-04 ZA ZA200400926A patent/ZA200400926B/xx unknown
-
2007
- 2007-12-26 JP JP2007334545A patent/JP4944759B2/ja not_active Expired - Lifetime
-
2015
- 2015-09-22 LU LU92835C patent/LU92835I2/xx unknown
- 2015-10-12 NO NO2015022C patent/NO2015022I1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0210541B8 (pt) | compostos derivados diamínicos; compostos intermediários para a preparação destes compostos; composição medicinal compreendendo ditos compostos; e usos dos mesmos para prevenir e/ou tratar trombose, embolia e outras doenças relacionadas | |
MY153231A (en) | Diamine derivatives | |
RU2345993C2 (ru) | ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa | |
BR0316586A (pt) | Derivados de diidropirano indol-3, 4-dione e derivados de 3-ácido oxoacético 2-hidroximetilindol substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) | |
MXPA05006989A (es) | Derivados de diamina. | |
WO2003016302A1 (fr) | Derives de diamine | |
MA28008A1 (fr) | Derives pyridyle et leur utilisation en tant qu'agents therapeutiques | |
WO1990004389A1 (en) | Use of resiniferatoxin and analogues thereof to cause sensory afferent c-fiber and thermoregulatory desensitization | |
DE69324151D1 (de) | Inhibitoren des arginin-ketoamid-enzyms | |
EA200300713A1 (ru) | Производные бензимидазола и пиридилимидазола в качестве лигандов рецепторов гамма-аминомасляной кислоты | |
BR0316585A (pt) | Derivados de ácido glioxìlico aril, ariloxi e alquiloxi 1h-indol-3-il substituìdos como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) | |
ES2185307T3 (es) | Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion. | |
BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
JP2015522032A (ja) | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 | |
UY26564A1 (es) | Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos | |
Fareed et al. | Small-molecule direct antithrombins: argatroban | |
HU206183B (en) | Process for producing composition comprising fibrinolytic and carbacyline derivative and suitable for treating thrombosis | |
KR950703527A (ko) | 프로스타글란딘 유도체 | |
ES2046309T3 (es) | Un procedimiento para preparar un derivado de indano. | |
ES2158223T3 (es) | Utilizacion de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de las enfermedades asociadas con la presencia de oxigeno activo y de radicales libres. | |
Abshagen | Organic nitrates | |
NO167147C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive tetrahydroisoksazolo(4,5-c)pyridinderivater. | |
JP4175887B2 (ja) | 新規血管狭窄治療剤または予防剤 | |
EP1874322A1 (en) | Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP) Free format text: TRANSFERIDO POR INCORPORCAO DE: DAIICHI PHARMACEUTICAL CO., LTD. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/12/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2727 DE 11/04/2023 POR TER SIDO INDEVIDA, UMA VEZ QUE A VIGENCIA DA PATENTE TERMINOU EM 20/06/2022. |